Detail Cantuman Kembali
Studi Penggunaan Obat Pada Pasien Hepatoma Rumkital Di Dr. Ramelan Surabaya
- Bagikan:
Hepatoma is one of liver cell cancer type. Occupies sequence to ten often in world and five in Indonesia. The purpose of this study was to analyze the drug utilization in patients with hepatocellular carcinoma who were hospitalized during January 2006 until March 2008. This study include the demography of the hepatocellular carcinoma patients, general profile patient of factor risk, complication, drug : used, and drug interaction in hepatocellular carcinoma. The retrospective method was used in this study with descriptive analysis. Result from demography data indicates that man more suffering hepatocellular carcinoma (100% is man), respectively. General patient hepatocellular carcinoma at the geriatri (age 60-69 was 60%). 12,5% exit patient from hospital in recavering condition, 68,8% with improveed condition, 9,4% with comphision return and 9,4% were died in the hospital. Not all patient at this study given chemotherapy. 53,1% patients with chemotheraphy and 46,8% patients non-chemotheraphy. Chemotheraphy used were fluorouracil (88,2%), combination 5-FU-cyclophosphamide (5,9%), doxorubicin, vincristin (5,9%), combination 5-FUcapechitabine (5,9%) an capechitabin (5,9%). The other treatment were treatment used to sign and complication disease is diuretic, PPM, antacid, H2 inhibitor, prokinetic, vitamin K, antifibrinolitic, antiintlamasi, antibiotic, antiphyretic, antidiarea, anticonstipation, corticosteroid, ACE inhibitor, canal calcium blokker, antidepresan, suplemen dan vitamin, antidiabetes, cardiotonic, albumin, and infus PRC.
Hidayati, Sholihatil - Personal Name
6B.S Hid s
6B.S Hid s
Text
Indonesia
Fakultas Farmasi UNAIR
2008
Surabaya
xiii, 110p.; 30cm
LOADING LIST...
LOADING LIST...